Moreover, only 1 of those studies adjusted for chemotherapy, whereas this study evaluated HDL-C over a long follow-up period and accounted for the effects of chemotherapy, tamoxifen, aromatase inhibitors, and dyslipidemia medications, all of which affect lipid profiles [18, 25]. Here, CYP19A1 is linked to metabolic syndrome.